According to a recent LinkedIn post from Zeto Inc, the company is showcasing multiple EEG solutions on the final day of the American Academy of Neurology Annual Meeting 2026. The post highlights live demonstrations of Zeto ONE for hospitals, the newly FDA-cleared New Wave EEG solution for clinics, and NeuroNotis, an AI-powered seizure detection report reviewed by registered EEG technologists.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Zeto is emphasizing a full-stack offering that spans hospital and clinic settings, as well as AI-enabled reporting workflows. For investors, this focus on FDA-cleared products and AI-based diagnostics support could indicate efforts to deepen clinical adoption, expand recurring software or service revenue, and strengthen the company’s competitive positioning in the neurology and EEG diagnostics market.
By promoting these capabilities at a major neurology conference, Zeto appears to be targeting neurologists, hospital systems, and outpatient clinics that influence purchasing decisions for EEG infrastructure. If the technology gains traction among these stakeholders, it could translate into increased sales of hardware and software bundles, potentially improving revenue visibility and enhancing the firm’s appeal as a specialized neurodiagnostics platform provider.